Cargando…

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma

Liver hepatocellular carcinoma (LIHC) is the most common primary liver cancer and the main cause of death in patients with cirrhosis. LRP1B is found to involve in a variety of cancers, but the association of LRP1B mutation with tumor mutation burden (TMB) and prognosis of LIHC is rarely studied. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ge, Mu, Han, Fang, Feng, Zhou, Hongyuan, Li, Huikai, Wu, Qiang, Xiong, Qingqing, Cui, Yunlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239668/ https://www.ncbi.nlm.nih.gov/pubmed/35777027 http://dx.doi.org/10.1097/MD.0000000000029763

Ejemplares similares

The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma
por: Wang, Mengmeng, et al.
Publicado: (2021)

LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
por: Wang, Longrong, et al.
Publicado: (2021)

LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma
por: Liu, Fahui, et al.
Publicado: (2021)

Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
por: Hu, Sizhe, et al.
Publicado: (2021)

Retracted: Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma
por: Xu, Jian, et al.
Publicado: (2021)

Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma
por: Sun, Lin, et al.
Publicado: (2017)

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma
por: Gabbia, Daniela, et al.
Publicado: (2023)

The Effect of Ferroptosis-Related Genes on Prognosis and Tumor Mutational Burden in Hepatocellular Carcinoma
por: Zhang, Hao, et al.
Publicado: (2021)

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression
por: Zhu, Xiaolin, et al.
Publicado: (2017)

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020)

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2020)

Diagnosis and prognosis models for hepatocellular carcinoma patient’s management based on tumor mutation burden
por: Tang, Bufu, et al.
Publicado: (2021)

Identification of two novel LRP5 mutations in families with familial exudative vitreoretinopathy
por: Fei, Ping, et al.
Publicado: (2014)

Novel LRP6 Mutations Causing Non-Syndromic Oligodontia
por: Lee, Yejin, et al.
Publicado: (2022)

CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer
por: Huang, Taobi, et al.
Publicado: (2021)

Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients
por: Ma, Xiangming, et al.
Publicado: (2018)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
por: Chen, Hao, et al.
Publicado: (2019)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma
por: Zhang, Rui, et al.
Publicado: (2021)

Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
por: Chen, Hao, et al.
Publicado: (2019)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Functional Analysis LRP6 Novel Mutations in Patients with Coronary Artery Disease
por: Xu, Yujun, et al.
Publicado: (2014)

Novel mutations in LRP6 highlight the role of WNT signaling in tooth agenesis
por: Ockeloen, Charlotte W., et al.
Publicado: (2016)

Synergistic Mutations of LRP6 and WNT10A in Familial Tooth Agenesis
por: Chu, Kuan-Yu, et al.
Publicado: (2021)

Osteoporosis, Fractures, and Blindness Due to a Missense Mutation in the LRP5 Receptor
por: Littman, Jake, et al.
Publicado: (2023)

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy
por: Zhu, Mingyu, et al.
Publicado: (2022)

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer
por: Zhang, Min, et al.
Publicado: (2020)

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast Cancer
por: Hao, Shuai, et al.
Publicado: (2022)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma
por: Wong, Mary, et al.
Publicado: (2021)

Osteoporosis-Pseudoglioma in a Mauritanian Child due to a Novel Mutation in LRP5
por: Biha, Noura, et al.
Publicado: (2016)

Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort
por: Li, Chunbo, et al.
Publicado: (2022)

Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
por: Liu, Zaoqu, et al.
Publicado: (2021)

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer
por: Guo, Xiong, et al.
Publicado: (2021)

High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2021)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma
por: Zhao, Yulan, et al.
Publicado: (2022)

Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma
por: Franses, Joseph W, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ai7j9lhbebvph1tjjm5c1hh9o0